Disposition of indomethacin in preterm infants

Paul S. Lietman, R. Bhat, D. Vidyasagar, M. Vadapalli, C. Whalley, E. Fisher, A. Hastreiter, M. Evans

Research output: Contribution to journalArticle

Abstract

Indomethacin is currently used for the pharmacologic closure of PDA in preterm infants with respiratory distress syndrome. However, the response to the drug has been variable and the disposition of the drug in preterm infants is not well understood. We studied the pharmacokinetics of indomethacin in nine preterm infants with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 weeks. Three different dose schedules (0.1, 0.25, 0.3 mg/kg/dose) were used. The plasma half-life of indomethacin ranged from 11 to 20 hours. Peak levels were achieved within four hours and ranged from 0.027 to 0.310 μg/ml. The half-life in infants 32 weeks. Protein-binding studies with 14C indomethacin showed that 98% of indomethacin was protein bound. Absorption of orally administered indomethacin appears to be poor and incomplete. No immediate major complications could be correlated to indomethacin therapy in this study.

Original languageEnglish (US)
Pages (from-to)305-308
Number of pages4
JournalJournal of Pediatrics
Volume95
Issue number2
DOIs
StatePublished - 1979
Externally publishedYes

Fingerprint

Premature Infants
Indomethacin
Half-Life
Newborn Respiratory Distress Syndrome
Protein Binding
Birth Weight
Pharmaceutical Preparations
Gestational Age
Appointments and Schedules
Pharmacokinetics
Proteins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Lietman, P. S., Bhat, R., Vidyasagar, D., Vadapalli, M., Whalley, C., Fisher, E., ... Evans, M. (1979). Disposition of indomethacin in preterm infants. Journal of Pediatrics, 95(2), 305-308. https://doi.org/10.1016/S0022-3476(79)80681-2

Disposition of indomethacin in preterm infants. / Lietman, Paul S.; Bhat, R.; Vidyasagar, D.; Vadapalli, M.; Whalley, C.; Fisher, E.; Hastreiter, A.; Evans, M.

In: Journal of Pediatrics, Vol. 95, No. 2, 1979, p. 305-308.

Research output: Contribution to journalArticle

Lietman, PS, Bhat, R, Vidyasagar, D, Vadapalli, M, Whalley, C, Fisher, E, Hastreiter, A & Evans, M 1979, 'Disposition of indomethacin in preterm infants', Journal of Pediatrics, vol. 95, no. 2, pp. 305-308. https://doi.org/10.1016/S0022-3476(79)80681-2
Lietman PS, Bhat R, Vidyasagar D, Vadapalli M, Whalley C, Fisher E et al. Disposition of indomethacin in preterm infants. Journal of Pediatrics. 1979;95(2):305-308. https://doi.org/10.1016/S0022-3476(79)80681-2
Lietman, Paul S. ; Bhat, R. ; Vidyasagar, D. ; Vadapalli, M. ; Whalley, C. ; Fisher, E. ; Hastreiter, A. ; Evans, M. / Disposition of indomethacin in preterm infants. In: Journal of Pediatrics. 1979 ; Vol. 95, No. 2. pp. 305-308.
@article{757938b591bf417c8f00fdd4ac432d23,
title = "Disposition of indomethacin in preterm infants",
abstract = "Indomethacin is currently used for the pharmacologic closure of PDA in preterm infants with respiratory distress syndrome. However, the response to the drug has been variable and the disposition of the drug in preterm infants is not well understood. We studied the pharmacokinetics of indomethacin in nine preterm infants with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 weeks. Three different dose schedules (0.1, 0.25, 0.3 mg/kg/dose) were used. The plasma half-life of indomethacin ranged from 11 to 20 hours. Peak levels were achieved within four hours and ranged from 0.027 to 0.310 μg/ml. The half-life in infants 32 weeks. Protein-binding studies with 14C indomethacin showed that 98{\%} of indomethacin was protein bound. Absorption of orally administered indomethacin appears to be poor and incomplete. No immediate major complications could be correlated to indomethacin therapy in this study.",
author = "Lietman, {Paul S.} and R. Bhat and D. Vidyasagar and M. Vadapalli and C. Whalley and E. Fisher and A. Hastreiter and M. Evans",
year = "1979",
doi = "10.1016/S0022-3476(79)80681-2",
language = "English (US)",
volume = "95",
pages = "305--308",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Disposition of indomethacin in preterm infants

AU - Lietman, Paul S.

AU - Bhat, R.

AU - Vidyasagar, D.

AU - Vadapalli, M.

AU - Whalley, C.

AU - Fisher, E.

AU - Hastreiter, A.

AU - Evans, M.

PY - 1979

Y1 - 1979

N2 - Indomethacin is currently used for the pharmacologic closure of PDA in preterm infants with respiratory distress syndrome. However, the response to the drug has been variable and the disposition of the drug in preterm infants is not well understood. We studied the pharmacokinetics of indomethacin in nine preterm infants with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 weeks. Three different dose schedules (0.1, 0.25, 0.3 mg/kg/dose) were used. The plasma half-life of indomethacin ranged from 11 to 20 hours. Peak levels were achieved within four hours and ranged from 0.027 to 0.310 μg/ml. The half-life in infants 32 weeks. Protein-binding studies with 14C indomethacin showed that 98% of indomethacin was protein bound. Absorption of orally administered indomethacin appears to be poor and incomplete. No immediate major complications could be correlated to indomethacin therapy in this study.

AB - Indomethacin is currently used for the pharmacologic closure of PDA in preterm infants with respiratory distress syndrome. However, the response to the drug has been variable and the disposition of the drug in preterm infants is not well understood. We studied the pharmacokinetics of indomethacin in nine preterm infants with birth weights ranging from 800 to 1,960 gm and gestational ages of 28 to 36 weeks. Three different dose schedules (0.1, 0.25, 0.3 mg/kg/dose) were used. The plasma half-life of indomethacin ranged from 11 to 20 hours. Peak levels were achieved within four hours and ranged from 0.027 to 0.310 μg/ml. The half-life in infants 32 weeks. Protein-binding studies with 14C indomethacin showed that 98% of indomethacin was protein bound. Absorption of orally administered indomethacin appears to be poor and incomplete. No immediate major complications could be correlated to indomethacin therapy in this study.

UR - http://www.scopus.com/inward/record.url?scp=58149406692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149406692&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(79)80681-2

DO - 10.1016/S0022-3476(79)80681-2

M3 - Article

AN - SCOPUS:58149406692

VL - 95

SP - 305

EP - 308

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 2

ER -